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Nitric oxide (NO) is involved in the pathogenesis of acute and chronic inflammatory
conditions, namely in allergic contact dermatitis (ACD). However, the mechanism by
which NO acts in ACD remains elusive. The present study focuses on the effects of dif-
ferent contact sensitizers (2,4-dinitrofluorbenzene, 1,4-phenylenediamine, nickel sul-
fate), the inactive analogue of DNFB, 2,4-dichloronitrobenzene, and two irritants
(sodium dodecyl sulphate and benzalkonium chloride) on the expression of the induc-
ible isoform of nitric oxide synthase (iNOS) and NO production in skin dendritic cells.
It was also studied the role of different immunosuppressive drugs on iNOS expression
and NO production. Only nickel sulfate increased the expression of iNOS and NO pro-
duction being these effects inhibited by dexamathasone. In contrast, cyclosporin A and
sirolimus, two other immunosuppressive drugs tested, did not affect iNOS expression
triggered by nickel.
Keywords Cyclosporin A, Dexamethasone, iNOS, Nickel Sulfate, Nitric Oxide,
Sirolimus, Skin Dendritic Cell.
Address correspondence to M.T. Cruz, Faculdade de Farmácia, Universidade de Coim-
bra, Rua do Norte, Coimbra, Portugal; E-mail: trosete@ff.uc.pt
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INTRODUCTION
Dendritic cells (DCs) are ubiquitously distributed migratory antigen present-
ing cells, derived from CD34+ bone marrow stem cells that have the unique
capacity to prime naïve T cells. DCs also regulate various effectors cell-functions
and, therefore, play central roles in modulating the immune response, namely
in allergic contact dermatitis (ACD).(1–3)
Among all the contact sensitizers, nickel is the most frequent cause of
ACD. This hapten increases the expression of DC surface markers essential
for antigen presentation, such as the molecules of the major histocompatibility
complex class II and costimulatory molecules(4–10) and increases chemokine
production and chemokine receptor expression(11–14), thereby favoring antigen
presentation. In DC, contact sensitizers activate mitogen-activated protein
kinases(15–21). We previously have reported that nickel sulfate activates the
transcription nuclear factor kappa B (NF-kB) and the transcription factor
activator protein-1 (AP-1) and induces the expression of inducible isoform of
nitric oxide synthase (iNOS) in mouse skin DC(22). However, the effect of other
skin contact sensitizers and irritants on iNOS expression and nitric oxide
(NO) production was never addressed before.
NO, a highly reactive radical produced from the amino acid L-arginine by
the enzyme iNOS, mediates various physiological functions in the skin, rang-
ing from the regulation of cutaneous blood flow to melanogenesis(23, 24), and
modulates antigen presentation.(25) If produced in excess, NO combines with
superoxide anion to form peroxynitrite that has been considered responsible
for tissue injury in skin inflammatory processes, such as ACD(26–30). There-
fore, in this work we studied the effect of different skin sensitizers that induce
ACD on NO production by skin dendritic cells.
Sirolimus, cyclosporine A, and dexamethasone are clinically relevant
immunosuppressive drugs with distinct molecular mechanisms of action,
exhibiting different immunoregulatory profiles. Although the effect of these
drugs on dendritic cell differentiation, migration, and maturation has been
reported previously(31), their direct effects on iNOS expression and NO produc-
tion triggered by contact sensitizers remain unknown.
The present study focuse on the effects of different contact sensitizers
(2,4-dinitrofluorbenzene, 1,4-phenylenediamine, nickel sulfate), the inac-
tive analogue of DNFB, 2,4-dichloronitrobenzene (DCNB), and of two
irritants (sodium dodecyl sulphate [SDS] and benzalkonium chloride [BC]),
on the expression and activity of iNOS in skin DC. Moreover, it we also
studied the role of different immunosuppressive drugs on iNOS expression
and NO production. As an experimental model of a DC we used a fetal
skin-derived dendritic cell line (FSDC), that has morphological, phenotypi-
cal, and functional characteristics of immature skin DC, the Langerhans
cells(32).
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iNOS Expression by Skin Sensitizers 227
MATERIAL AND METHODS
Nickel sulfate, dexamethasone, benzalkonium chloride, and cyclosporin A were
from Sigma Chemical Co. (Madrid, Spain). Sodium dodecyl sulphate was from
GE Healthcare (Carnaxide, Portugal) and sirolimus was from Calbiochem
(San Diego, CA, USA). The rabbit polyclonal anti-iNOS was from Abcam (Cam-
bridge, UK). The alkaline phosphatase linked antirabbit IgG (H + L) antibody
and the ECF substrate were purchased from GE Healthcare. Alexa Fluor 488-
conjugated goat antirabbit antibody was from Molecular Probes (Leiden, The
Netherlands) and the mounting medium for fluorescence, Vectashield, was
obtained from Vector Laboratories, (Burlingame, CA, USA). The fetal calf
serum was from Biochrom KG (Berlin, Germany) and trypsin from Invitrogen
(Paisley, UK). The proteases inhibitor cocktail was from Roche (Carnaxide,
Portugal). DCNB, DNFB, and phenylenediamine (PPD) were from Aldrich Chem-
ical Company (Madrid, Spain). All other reagents were from Sigma Chemical Co.
Cell Culture and Chemicals
The fetal mouse skin dendritic cell line FSDC was kindly supplied by
Dr. G. Girolomoni(32) and cultured in endotoxin free Iscove´s medium supple-
mented with 10 % (v/v) fetal calf serum, 1 % (w/v) glutamine, 3.02 g/l sodium
bicarbonate, 100 μg/ml streptomycin, and 100 U/ml penicillin. For Western
blot analysis FSDC were plated at 2 × 106 cells/well in 6-well culture plates,
for 24 hr, prior to treatment with the contact sensitizers or with the contact
sensitizer nickel sulfate in the presence of the different immunosuppressors.
For nitrite and MTT measurements the cells were plated at 0.2 × 106 cells/well
in 48-well culture plates in the presence of NiSO4 and the immunosuppressors
for 48 hrs. SDS (50 μg/ml), BC (1 μg/ml), PPD (50 μg/ml), and NiSO4 (50 μg/ml)
were dissolved in saline, while DNFB (1 μg/ml) and DCNB (1 μg/ml) were first
solubilized in dimethyl sulphoxide. Dimethyl sulphoxide concentration never
exceeded 0.025% in the culture medium.
MTT Assay
Assessment of MTT reduction by metabolically active cells was made by a
colorimetric assay, using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide (MTT) as previously reported(33). The cells (0.2 × 106 cells/well),
cultured in 48-well microplates, were incubated for 48 hr with culture medium
alone (control), with NiSO4 (50 μg/ml), or with the contact sensitizer in the
presence of the different immunosuppressors. After removal of cell-free super-
natants for the nitrite assay, 400 μl of culture medium and 40 μl of MTT solu-
tion (5 mg/ml in PBS) were added to each well. The microplates were further
incubated at 37°C for 1 hr. Supernatants were then discarded and 300 μl of
acidified isopropanol (0.04 N HCl in isopropanol) were added to the cultures
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and mixed thoroughly to dissolve the dark blue crystals of formazan. Formazan
quantification was performed using an automatic plate reader (SLT, Austria)
at 570 nm, with a reference wavelength of 620 nm.
Nitrite Measurement
The production of NO was measured by the accumulation of nitrite in the
culture supernatants, using a colorimetric reaction with the Griess reagent(34).
Briefly, after FSDC stimulation with culture medium alone (control), or with
NiSO4 (50 μg/ml), or with the contact sensitizer in the presence of the different
immunosuppressors, for 48 hr, the culture supernatants were collected and
diluted with equal volumes of the Griess reagent (0.1% [w/v] N-(1-naphthyl)
ethylenediamine dihydrochloride, 1 % [w/v] sulphanilamide:5 % [w/v] H3PO4),
during 10 min. The absorbance at 550 nm was measured after 20-min incuba-
tion in an automated plate reader (SLT). Nitrite concentration was deter-
mined from a sodium nitrite standard curve.
Western Blot Analysis
For immunodetection of iNOS, cells were treated with culture medium
(control), with the contact sensitizers NiSO4 (50 μg/ml), DNFB (1 μg/ml), and
PPD (50 μg/ml), with the irritants SDS (50 μg/ml) and BC (1 μg/ml), and with
the inactive chemical DCNB (1μg /ml). In another set of experiments, cells
were treated with the contact sensitizer NiSO4 in the presence of the different
immunosuppressors, and with the immunosuppressors alone (data not
shown), for 24 hr. After treatment, cells were washed with PBS and total cell
lysates were obtained after harvesting the cells in a sonication buffer contain-
ing 0.25 M sucrose, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 2 mM sodium orto-
vanadate, 1mM dithiothreitol, and the protease inhibitor cocktail. The lysates
were then incubated on ice for 30 min and sonicated on ice at low amplitude
(four times for 4 sec at 20 μm peak to peak) to disrupt the cells. Protein con-
centration was determined using the bicinchoninic acid method. Protein sam-
ples were separated on a 12% (v/v) SDS-PAGE and transferred to a PVDF
membrane. The membrane was blocked with 5% (w/v) dry milk in Tris-buffered
saline with 0.1% (v/v) Tween 20, for 1 hr.
The level of iNOS protein was detected using a rabbit polyclonal anti-
mouse iNOS antibody (1:200) for 1 hr, followed by incubation 1 hr at room
temperature, with antirabbit IgG antibodies coupled to alkaline phosphatase,
at 1:20,000 dilution. The immune complexes were detected using the ECF sys-
tem (GE Healthcare), and the membranes were then scanned with blue-
excited fluorescence on the Storm 860 (Amersham Biosciences), according to
the manufacturer’s instructions. The signals were analyzed using an image
analyzer. To demonstrate equivalent protein loading the membranes were
stripped and reprobed with an antiactin antibody (1:7500).
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iNOS Expression by Skin Sensitizers 229
Immunofluorescence Microscopy
For immunofluorescence analysis, FSDC cells grown on Lab-Tek chamber
slide with cover (0.2 × 106 cells/slide) were treated, for 24 hrs, with the con-
tact sensitizers NiSO4 (50 μg/ml), DNFB (1 μg/ml), and PPD (50 μg/ml), with
the irritants SDS (50 μg/ml) and BC (1 μg/ml), and with the inactive chemical
DCNB (1μg /ml). In another set of experiments, cells were treated with the
contact sensitizer NiSO4 in the presence of the different immunosuppressors,
namely sirolimus (1 nM), dexamethasone (1 μM), and cyclosporin A (0.83
μM). The cells were then washed with PBS and fixed and permeabilized with
methanol/acetone (1:1), for 10 min. Nonspecific binding was blocked by incu-
bating the cells with 0.2 % gelatine in PBS supplemented with 0.1 % Tween
20, for 45 min at room temperature. Cells were then incubated for 120 min at
room temperature, with a rabbit polyclonal antibody directed against iNOS
(20 μg/ml).
After rinsing with PBS the cells were incubated with Alexa Fluor 488 con-
jugated goat antirabbit antibody (1:500) in 0.5% BSA-PBS, for 45 min. The
chamber slide was rinsed and mounted with the mounting medium for fluo-
rescence, Vectashield. Images from cells labelled with anti-iNOS were
acquired on a Zeiss Axiovert 200 fluorescence microscope. Control experi-
ments consisted of processing the same preparations as described, except for
omission of the primary antibody, and resulted in no specific staining.
Data Analysis
Results are presented as mean ± SEM of the indicated number of experi-
ments. Mean values were compared using one-way ANOVA followed by the
Bonferroni´s multiple comparison test. The significance level was 0.05.
RESULTS
Nickel Sulfate Increases iNOS Expression and NO Production
We evaluated the effect of the sensitizers nickel, DNFB, PPD, the irritants
SDS, BC, and the nonsensitizer DCNB on the expression of iNOS protein in
dendritic cells. Our results demonstrated that only nickel sulfate increased
iNOS expression by FSDC (Figure 1, lane 4), detected by Western blot, and
slightly increased nitrite production (Figure 2), determined by the Griess
reagent. As shown in Figure 2, stimulation of the cells with NiSO4 for 48 hr
increased nitrite production, from 100% when FSDC were incubated with cul-
ture medium alone, to 109.5 ± 1.2%, when FSDC were incubated with 50 μg/
ml NiSO4 (p < 0.05), reflecting an increase in NO production. The assay of cel-
lular MTT reduction did not show any significant toxic effect induced by
NiSO4 for the concentration used in these experiments (data not shown).
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Dexamethasone Inhibits iNOS expression and NO Production
We also investigated the effect of three immunosuppressive drugs, dexam-
ethasone, cyclosporin A, and sirolimus, on iNOS expression and NO produc-
tion stimulated by the contact sensitizer nickel sulfate on skin DC. After
FSDC stimulation with the sensitizer nickel in the presence of dexamethasone
(1 μM), nitrite production induced by nickel was reduced to 72.2 ± 5.3% of the
control (p < 0.001) (Figure 2). Cyclosporin A (0.83 μM) and sirolimus (1 nM)
did not modify the increase of nitrite production triggered by the contact sensi-
tizer (Figure 2) (108.4 ± 0.9 and 111.4 ± 1.4 % of control, respectively). Western
blot was used to examine the effect of immunosuppressive drugs on the
Figure 1: Effect of contact sensitizers and irritants on iNOS expression in FSDC cells. FSDC cells
(2 × 106 cells) were incubated in culture medium alone (control, lane 1), or with 1 μg/ml DNFB
(lane 2), 50 μg/ml PPD (lane 3), 50 μg/ml NiSO4 (lane 4), 1 μg/ml DCNB (lane 5), 50 μg/ml SDS
(lane 6), or 1 μg/ml BC (lane 7) for 24 hr. Total cell extracts were electrophoresed through SDS-
PAGE, transferred to PVDF membranes and subjected to Western blot analysis using an anti-
iNOS antibody. (A) The membranes were stripped and reprobed with an antiactin antibody
to confirm equal protein loading (B). The results were quantified by scanning the membrane
with a fluorescence scanner and analyzed using an image analyzer. Each value represents
the mean ± SEM from 4 experiments.**p < 0.01.
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iNOS Expression by Skin Sensitizers 231
modulation of iNOS protein expression induced by NiSO4. As indicated in Fig-
ure 3, nonstimulated cells (lane 1) expressed low levels of iNOS protein, but
the expression of the protein increased after stimulation of cells with 50 μg/ml
NiSO4 for 24 hr (lane 2). The basal expression of iNOS protein in control cells
is probably due to the presence of fetal calf serum (10%) in the culture
medium, which per se activates the cells to some extent.
Dexamethasone inhibited the expression of iNOS in cells stimulated with
nickel sulfate (Figure 3, lane 3), as well as the basal iNOS expression. In con-
trast, neither cyclosporine A nor sirolimus modified the levels of iNOS protein
(Figure 3, lanes 4 and 5, respectively). This decrease in protein expression
caused by dexamethasone correlated well with the maximal inhibitory effect
on nitrite production, as shown in Figure 2. The immunosuppressive drug con-
centrations used in this work were chosen based on the absence of toxicity to
FSDC cells, as revealed by the MTT assay (data not shown). Dexamethasone
slightly decreased the MTT reduction, to 90.1 ± 6.2 % (n = 3) of the control, but
this effect was not statistically significant (data not shown).
Dexamethasone Inhibits iNOS Immunofluorescence
Immunofluorescent labelling of FSDC cells with the anti-iNOS polyclonal
antibody was performed to confirm the results obtained by Western blot
Figure 2: Effect of immunosuppressors on nitrite production induced by the contact sensitizer
nickel sulfate in FSDC cells. FSDC cells (0.2 × 106 cells) were maintained in culture medium
(control) or were incubated with 50 μg/ml NiSO4 or with NiSO4 in the presence of dexametha-
sone, cyclosporin A, or sirolimus, at the indicated concentrations, for 48 hr. Nitrite levels in the
culture supernatants were detected by the Griess reaction as described in the Material and
Methods section. Each value represents the mean ± SEM from the indicated number of exper-
iments, performed in duplicate.*p < 0.05, ***p < 0.001.
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232 M.T. Cruz et al.
(Figure 4). Nickel sulfate slightly increased iNOS as compared with the cells
maintained in culture medium. In addition, the other contact sensitizers and
irritants studied, as well as DCNB, did not modify iNOS fluorescence. These
results are in agreement with those obtained by Western blot (Figure 1) and
indicate that the expression of iNOS is upregulated by the sensitizer NiSO4 in
Figure 3: Effect of immunosuppressors on iNOS expression induced by the contact sensitizer
nickel sulfate in FSDC cells. FSDC cells (2 × 106 cells) were incubated in culture medium alone
(control, lane 1), with 50 μg/ml NiSO4 (lane 2), or with NiSO4 in the presence of 1 μM dexam-
ethasone (lane 3), 0.83 μM cyclosporin A (lane 4), or 1 nM sirolimus (lane 5), for 24 hr. Total cell
extracts were electrophoresed through SDS-PAGE, transferred to PVDF membranes, and sub-
jected to Western blot analysis using an anti-iNOS antibody. (A) The membranes were
stripped and reprobed with an antiactin antibody to confirm equal protein loading (B). The
results were quantified by scanning the membrane with a fluorescence scanner and ana-
lyzed using an image analyzer. Each value represents the mean ± SEM from 3 experiments.
**p < 0.01; ***p < 0.001.
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iNOS Expression by Skin Sensitizers 233
Figure 4: Immunofluorescence of the iNOS protein in FSDC exposed to contact sensitizers
and irritants. FSDC cells (0.2 × 106 cells) were maintained for 24 hr in culture medium, in the
absence (control, A) or in the presence of 1 μg/ml DNFB (B), 50 μg/ml PPD (C), 50 μg/ml
NiSO4 (D), 1 μg/ml DCNB (E), 50 μg/ml SDS (F), or with 1 μg/ml BC (G). Immunostaining was
performed as described in Materials and Methods section (magnification 650×).
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FSDC. The results obtained by immunofluorescence also demonstrate that
dexamethasone is the unique immunosuppressor able to decrease the iNOS
expression triggered by the contact sensitizer nickel (Figure 5).
DISCUSSION
The aim of our study was to evaluate the effect of the contact sensitizers
DNFB, PPD, and nickel sulfate, and the irritants SDS and BC, on the iNOS
protein expression to known if there is a different DC response that could dis-
criminate between contact sensitizers and skin irritants. We have previously
demonstrated, in a mouse skin dendritic cell line, that the contact sensitizer
nickel sulfate increases iNOS expression and NO production in these skin
dendritic cells(22). However, the effect of other contact sensitizers and irritants
on iNOS expression and NO production in DC was not addressed before. Our
results demonstrated that only nickel sulfate increased iNOS expression by
FSDC (Figure 1, lane 4, and Figure 4) and slightly increased nitrite produc-
tion (Figure 2), reflecting an increase in NO production. Accordingly, other
Figure 5: Immunofluorescence of the iNOS protein in FSDC exposed to the contact sensitizer
nickel and to immunosuppressors. FSDC cells (0.2 × 106 cells) were incubated, for 24 hr, with 50
μg/ml NiSO4 (A), with NiSO4 in the presence of 0.83 μM cyclosporin A (B), 1 μM dexametha-
sone (C), or 1 nM sirolimus (D). Immunostaining was performed as described in Materials and
Methods section (magnification 650×).
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iNOS Expression by Skin Sensitizers 235
researchers demonstrated that NiCl2 and 2,4-dinitrochlorobenzene stimulate
different signal transduction pathways in monocyte-derived dendritic cells
and subsequently induce different phenotypic and functional changes in
them(4).
We also investigated the effect of three immunosuppressive drugs, dexam-
ethasone, cyclosporin A and sirolimus, on iNOS expression and NO production
induced by the contact sensitizer nickel sulphate, on skin DC. Dexamethasone
was the only immunosuppressant that inhibited NO production (Figure 2) and
iNOS expression (Figures 3 and 5D) triggered by nickel. Accordingly, dexam-
ethasone, but not cyclosporin A, was previously shown to inhibit DC activa-
tion stimulated by different haptens, namely nickel(35).
We have preliminary results (n = 2) showing that nickel sulfate increases
the expression of CD40 in this cell line and this increase was not inhibited by
dexamethasone (1 μM), cyclosporin A (0.83 μM), or sirolimus (1 nM), which
demonstrates that the inhibitory effect of dexamethasone on iNOS expression
is specific to this protein.
The role of NO in numerous skin diseases, including wound healing, burn
injury, ultraviolet light-induced sunburn erythema, psoriasis, irritant contact
dermatitis and ACD has been extensively documented. However, the mechanism
by which NO acts in ACD remains elusive(26, 36). Hyun et al.(37) demonstrated
that in a murine model of contact dermatitis, NO-releasing hydrocortisone
NCX 1022 provided faster and greater protective effects than hydrocortisone
alone. However, the researchers suggested that NO exerts a dual role in ACD,
exerting both beneficial and aggravating effects(27). Clinically, corticosteroids
are among the first line drugs in the therapy of autoimmune and allergic skin
diseases.
The present study highlights another mechanism, namely the inhibition
of the NO production, which can be responsible for the anti-inflammatory
properties of dexamethasone in skin dendritic cells. Accordingly, recent
reports showed that pimecrolimus, a nonsteroid calcineurin inhibitor, has lit-
tle effect on DC differentiation, maturation and immune function, in contrast
to corticosteroids that showed pronounced effects on DC(38–41). When compared
with calcineurin inhibitors, namely cyclosporin A and tacrolimus, corticoster-
oids have a unique and profound inhibitory effect on the generation and func-
tion of DC(42).
Manome et al.(43) demonstrated that dexamethasone and cyclosporin A
affect differently the maturation of monocyte-derived DC but both reduced
allostimulatory properties of DC despite induction of divergent molecular phe-
notypes(44). Matsue et al.(45) also demonstrated contrasting effects of
cyclosporin A, sirolimus, and dexamethasone on DC antigen presentation to T
cells. These studies are in agreement with our results demonstrating that dex-
amethasone, sirolimus, and cyclosporin A affect differently NO production and
iNOS expression induced by nickel sulfate in mouse skin dendritic cells
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(Figures 2, 3 and 5). Dexamethasone was the only immunosuppressant able to
inhibit NO production and iNOS expression.
The differential effect of immunosuppressant drugs on nickel-evoked up-
regulation of NOS and nitrite production in FSDC is most likely related to
their distinct mechanisms of action. Cyclosporin A binds to its intracellular
immunophilin receptor (cyclophilin A) and this complex decreases calcineurin
phosphatase-dependent nuclear translocation of the cytosolic nuclear factor
of activated T cells(46). Thus, the immunosuppressive effect of cyclosporin A is
primarily due to its direct suppression of T-cell activation, although this drug
may also have a direct effect on DC by mechanisms that are at least partly
independent of calcineurin inactivation(31). Our results showed that
cyclosporin A did not modify the levels of iNOS protein (Figure 3, lane 4 and
Figure 5C) and NO production (figure 2) elicited by the contact sensitizer
nickel sulfate in FSDC. Accordingly, in rat hepatocytes, cyclosporin A also
was without effect on iNOS expression and NO production triggered by inter-
leukin 1β(47).
Sirolimus (rapamycin) structurally resembles FK506 (tacrolimus).
Although both bind to the same intracellular immunophilin, termed 12-kDa
FK506-binding protein (FKBP12), the sirolimus-FKBP12 complex interacts
with a distinct molecular target, known as mammalian target of rapamycin
(mTOR), which results in the inhibition of multiple biochemical pathways crit-
ical for cytokine/growth factor-induced cellular proliferation, ribosome synthe-
sis, translation initiation, and cell cycle progression into S phase(46). Although
sirolimus was shown recently to inhibit DC migration and DC-mediated T-cell
activation(48), our results indicated that sirolimus did not modify the levels of
iNOS protein (Figure 3, lane 5, and Figure 5E) and NO production (Figure 2)
elicited by nickel sulfate.
Glucocorticoids, on the other hand, exert their potent immunosuppressive
and anti-inflammatory effects by inhibiting gene transcription, directly by
competing for DNA-binding sites in the promoter regions, or indirectly by
cross-coupling with many transcription factors, including the pro-inflamma-
tory transcription factors AP-1 and NF-kB(49). Since the promoter region of the
iNOS gene contains binding sites for NF-kB and AP-1(50), dexamethasone
inhibits iNOS expression and NO production by interfering with the NF-kB
and/or AP-1 signalling pathways(51,52). Accordingly, our previous work demon-
strated that, in FSDC cells, dexamethasone prevents granulocyte macrophage
colony-stimulating factor (GM-CSF)-induced NF-kB activation, iNOS expres-
sion, and NO production(53). The pathways regulating iNOS expression seem
to vary in different cells or different species(50).
We have previously demonstrated in this dendritic cell line (FSDC) and
published elsewhere that iNOS expression induced by several stimuli, namely
lipopolysaccharide, GM-CSF, and nickel sulphate, is clearly dependent on NF-
kB activation(22,33,54,55). Therefore, in this cell line this transcription factor is
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critical for iNOS expression, whereas in other cells, namely macrophages,
other transcription factors are also involved in iNOS expression, such as AP-1,
Stat 1 α, IRF-1, CREB, and C/EBP.
Therefore, in this dendritic cell line iNOS expression is dependent on NF-
kB activation and this justifies why only dexamethasone inhibited iNOS
expression in contrast to cyclosporine and sirolimus whose principal molecu-
lar mechanism of action is to inhibit calcineurin phosphatase activity. Accord-
ingly, nickel sulfate activates the NF-kB and AP-1 signalling pathways in
FSDC(22). NF-kB activation by nickel also was reported in human monocyte-
derived DC(15) and in human endothelial cells(56, 57). Moreover, in human air-
way epithelial cells, nickel-induced interleukin-8 expression was shown to be
dependent on AP-1(58) and in epithelial cells nickel activates AP-1 through an
oxidant-independent pathway(59).
CONCLUSION
We showed that nickel sulfate, in contrast with the effect of DNFB, PPD,
and the irritants SDS and BC, increased iNOS expression in skin DC. There-
fore, this endpoint cannot be used as an in vitro method to study the sensiti-
zation potential of chemicals or to discriminate between skin sensitizers and
irritants.
Moreover, as the AP-1 and NF-kB transcription factors are involved in
the iNOS expression induced by nickel sulfate, the inhibitory effect was
observed only for dexamethasone and not for the other immunosuppressors
studied, which do not significantly affect this pathway. This inhibitory effect
of dexamethasone on the iNOS/NO pathway in DC, apart from a known
effect on T cells and keratinocytes, may account for some of the anti-
inflammatory properties of topical corticosteroids observed in inflammatory
skin conditions(38–42). A more pronounced inhibition of dexamethasone in the
process of activation of DC by allergens, both during sensitization and the
afferent phase of ACD elicitation, can sustain why medium/potent topical
and systemic steroids are more effective in the treatment of ACD than the
recently commercialized topical immunosuppressors, tacrolimus and pime-
crolimus, which act through molecular mechanisms similar to cyclosporin A
and sirolimus.
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